MFSD10

Across TCGA pan-cancer cohorts, MFSD10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MFSD10 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MFSD10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MFSD10 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where MFSD10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.813	0.986	.003	30	view →
HNSC	DFS	Quartile	All	0.873	0.659	.010	23	view →
GBM	OS	Median	All	0.770	0.855	.027	5	view →
LSCC	OS	Quartile	III,IV	0.916	0.381	.013	4	view →
LUAD	DFS	Tertile	III,IV	0.993	0.520	.035	3	view →
PDAC	OS	Tertile	IV	0.395	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MFSD10–CCRCC (OS)

Open the CCRCC breakdown →